Delta4, founded in 2019, is an AI Drug Discovery TechBio company at the forefront of detecting relationships between drugs with a known safety profile and rare diseases. This allows us to unearth new indications that could potentially revolutionize the way treatments find their way to patients. With a dedicated team of professionals, ranging from computational biologists to intellectual property experts, Delta4 is driven by the singular mission of enhancing patient care across the globe.
By harnessing the power of our unique AI-powered platform, Hyper-C, Delta4 has been at the spearhead of drug repurposing and indication expansion. Our main goal is to pinpoint undetected correlations between existing drugs and diseases. Through this, we present new therapeutic options more swiftly, economically, and efficiently than ever before.
Operated by our highly skilled team of computational biologists, Hyper-C is our keystone in identifying these relationships. It’s not just about speed but the precision and accuracy with which we offer unique insights for drug repurposing and indication expansion.
Drug repurposing and indication expansion represent a paradigm shift, offering a cost-effective way to discover new uses for existing drugs. Our investment in Hyper-C is a testament to our commitment to revolutionizing the drug discovery space.
Kurt Herpel (CEO) is a pharma executive with vast experience in leading organizations. Besides big pharma, he is experienced in start-up situations and smaller enterprises.
Klaus Kratochwill (CSO) is a translational researcher, and biochemist by training. He is an expert in omics data generation and analysis. In Delta4, he is responsible for coordinating all scientific activities.
Alfred Steininger (CFO) is a financial professional with a deep knowledge of banking and capital markets. He has worked in a couple of different countries and for both large and small organizations.
At the core, Delta4 is more than just a company; it’s a collective of individuals passionate about finding better treatments for complex and rare diseases. Our team comprises computational biologists, medical and pharmaceutical experts, molecular biologists, full-stack developers, and intellectual property experts. The unifying force among us is the drive to aid patients worldwide. We’re not just here for innovation; we’re here to make a tangible difference.
Learn more about the vibrant and brilliant minds powering Delta4
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
The scientific aim of PerMediK is to support the development of a path towards personalized medicine in chronic kidney disease …
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital …
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and …
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for …
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified …
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its …
For media inquiries, partnership opportunities, or more information:
Thank you for your interest in Delta4. We are driven by innovation and the ambition to pave a brighter path in healthcare, transforming lives worldwide.